TG Therapeutics (NASDAQ:TGTX) Upgraded by StockNews.com to Hold Rating

StockNews.com upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a research report released on Tuesday morning.

TGTX has been the subject of a number of other research reports. The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Stock Up 3.5 %

TG Therapeutics stock opened at $35.62 on Tuesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market capitalization of $5.54 billion, a price-to-earnings ratio of -356.16 and a beta of 2.30. TG Therapeutics has a 1-year low of $12.93 and a 1-year high of $36.94. The business has a fifty day moving average price of $30.86 and a 200-day moving average price of $28.33.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. Equities research analysts forecast that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares in the company, valued at $20,313,443.28. The trade was a 1.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock worth $469,454,000 after buying an additional 209,190 shares in the last quarter. State Street Corp increased its stake in TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after buying an additional 2,398,015 shares in the last quarter. Soleus Capital Management L.P. increased its stake in TG Therapeutics by 5.8% during the 4th quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after buying an additional 146,702 shares in the last quarter. Clearbridge Investments LLC purchased a new stake in TG Therapeutics during the 4th quarter worth approximately $55,237,000. Finally, Northern Trust Corp increased its stake in TG Therapeutics by 8.6% during the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after buying an additional 120,785 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.